Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis
- PMID: 32100123
- DOI: 10.1007/s00415-020-09761-z
Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis
Abstract
Neurofilament light chain protein (NfL) is currently the most accurate cerebrospinal fluid (CSF) biomarker in amyotrophic lateral sclerosis (ALS) in terms of both diagnostic and prognostic value, but the mechanism underlying its increase is still a matter of debate. Similarly, emerging CSF biomarkers of neurodegeneration and neuroinflammation showed promising results, although further studies are needed to clarify their clinical and pathophysiological roles. In the present study we compared the diagnostic accuracy of CSF NfL, phosphorylated (p)-tau/total (t)-tau ratio, chitinase-3-like protein 1 (YKL-40) and chitotriosidase 1 (CHIT1), in healthy controls (n = 43) and subjects with ALS (n = 80) or ALS mimics (n = 46). In ALS cases, we also investigated the association between biomarker levels and clinical variables, the extent of upper motor neuron (UMN) and lower motor neuron (LMN) degeneration, and denervation activity through electromyography (EMG). ALS patients showed higher levels of CSF NfL, YKL-40, CHIT1, and lower values of p-tau/t-tau ratio compared to both controls and ALS mimics. Among all biomarkers, NfL yielded the highest diagnostic performance (> 90% sensitivity and specificity) and was the best predictor of disease progression rate and survival in ALS. NfL levels showed a significant correlation with the extent of LMN involvement, whereas YKL-40 levels increased together with the number of areas showing both UMN and LMN damage. EMG denervation activity did not correlate with any CSF biomarker change. These findings confirm the highest value of NfL among currently available CSF biomarkers for the diagnostic and prognostic assessment of ALS and contribute to the understanding of the pathophysiological and electrophysiological correlates of biomarker changes.
Keywords: Amyotrophic lateral sclerosis; Glial markers; Neurofilament light chain; Phosphorylated tau; Prognosis.
Similar articles
-
CSF chitinase proteins in amyotrophic lateral sclerosis.J Neurol Neurosurg Psychiatry. 2019 Nov;90(11):1215-1220. doi: 10.1136/jnnp-2019-320442. Epub 2019 May 23. J Neurol Neurosurg Psychiatry. 2019. PMID: 31123140
-
Significance of CSF NfL and tau in ALS.J Neurol. 2018 Nov;265(11):2633-2645. doi: 10.1007/s00415-018-9043-0. Epub 2018 Sep 5. J Neurol. 2018. PMID: 30187162
-
Exploiting the role of CSF NfL, CHIT1, and miR-181b as potential diagnostic and prognostic biomarkers for ALS.J Neurol. 2024 Dec;271(12):7557-7571. doi: 10.1007/s00415-024-12699-1. Epub 2024 Sep 28. J Neurol. 2024. PMID: 39340541 Free PMC article.
-
CSF and blood levels of Neurofilaments, T-Tau, P-Tau, and Abeta-42 in amyotrophic lateral sclerosis: a systematic review and meta-analysis.J Transl Med. 2024 Oct 21;22(1):953. doi: 10.1186/s12967-024-05767-7. J Transl Med. 2024. PMID: 39434139 Free PMC article.
-
Chitinases as a potential diagnostic and prognostic biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis.Neurol Sci. 2024 Jun;45(6):2489-2503. doi: 10.1007/s10072-024-07301-5. Epub 2024 Jan 9. Neurol Sci. 2024. PMID: 38194198 Free PMC article.
Cited by
-
CSF p-tau as a potential cognition impairment biomarker in ALS.Front Neurol. 2022 Nov 1;13:991143. doi: 10.3389/fneur.2022.991143. eCollection 2022. Front Neurol. 2022. Retraction in: Front Neurol. 2024 Mar 04;15:1392563. doi: 10.3389/fneur.2024.1392563. PMID: 36388201 Free PMC article. Retracted.
-
Phenotypic correlates of serum neurofilament light chain levels in amyotrophic lateral sclerosis.Front Aging Neurosci. 2023 Mar 15;15:1132808. doi: 10.3389/fnagi.2023.1132808. eCollection 2023. Front Aging Neurosci. 2023. PMID: 37009451 Free PMC article.
-
Role of Blood Neurofilaments in the Prognosis of Amyotrophic Lateral Sclerosis: A Meta-Analysis.Front Neurol. 2021 Oct 6;12:712245. doi: 10.3389/fneur.2021.712245. eCollection 2021. Front Neurol. 2021. PMID: 34690913 Free PMC article.
-
Diagnostic value of neurofilaments in differentiating motor neuron disease from multifocal motor neuropathy.J Neurol. 2024 Jul;271(7):4441-4452. doi: 10.1007/s00415-024-12355-8. Epub 2024 Apr 29. J Neurol. 2024. PMID: 38683209 Free PMC article.
-
Threshold tracking transcranial magnetic stimulation and neurofilament light chain as diagnostic aids in ALS.Ann Clin Transl Neurol. 2024 Jul;11(7):1887-1896. doi: 10.1002/acn3.52095. Epub 2024 Jun 19. Ann Clin Transl Neurol. 2024. PMID: 38894662 Free PMC article.
References
-
- Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1(5):293–299 - DOI
-
- de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J, Mills K, Mitsumoto H, Nodera H, Shefner J, Swash M (2008) Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol 119(3):497–503. https://doi.org/10.1016/j.clinph.2007.09.143 - DOI - PubMed
-
- Gille B, De Schaepdryver M, Dedeene L, Goossens J, Claeys KG, Van Den Bosch L, Tournoy J, Van Damme P, Poesen K (2019) Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry 90(12):1338–1346. https://doi.org/10.1136/jnnp-2018-319586 - DOI - PubMed
-
- Steinacker P, Feneberg E, Weishaupt J, Brettschneider J, Tumani H, Andersen PM, von Arnim CA, Böhm S, Kassubek J, Kubisch C, Lulé D, Müller HP, Muche R, Pinkhardt E, Oeckl P, Rosenbohm A, Anderl-Straub S, Volk AE, Weydt P, Ludolph AC, Otto M (2016) Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry 87(1):12–20. https://doi.org/10.1136/jnnp-2015-311387 - DOI - PubMed - PMC
-
- Poesen K, De Schaepdryver M, Stubendorff B, Gille B, Muckova P, Wendler S, Prell T, Ringer TM, Rhode H, Stevens O, Claeys KG, Couwelier G, D'Hondt A, Lamaire N, Tilkin P, Van Reijen D, Gourmaud S, Fedtke N, Heiling B, Rumpel M, Rödiger A, Gunkel A, Witte OW, Paquet C, Vandenberghe R, Grosskreutz J, Van Damme P (2017) Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology 88(24):2302–2309. https://doi.org/10.1212/WNL.0000000000004029 - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous